| Literature DB >> 33867852 |
Jiaxin Yan1,2, Chunli Wang1,3, Xiaomei Jiang3, Yiqu Wei3, Qun Wang3, Kunli Cui3, Xiao Xu3, Feng Wang4, Lei Zhang3.
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer death, which accounts for approximately 10% of all new cancer cases worldwide. Surgery is the main method for treatment of early-stage CRC. However, it is not effective for most metastatic tumors, and new treatment and diagnosis strategies need to be developed. Photosensitizers (PSs) play an important role in the treatment of CRC. Phototherapy also has a broad prospect in the treatment of CRC because of its low invasiveness and low toxicity. However, most PSs are associated with limitations including poor solubility, poor selectivity and high toxicity. The application of nanomaterials in PSs has added many advantages, including increased solubility, bioavailability, targeting, stability and low toxicity. In this review, based on phototherapy, we discuss the characteristics and development progress of PSs, the targeting of PSs at organ, cell and molecular levels, and the current methods of optimizing PSs, especially the application of nanoparticles as carriers in CRC. We introduce the photosensitizer (PS) targeting process in photodynamic therapy (PDT), the damage mechanism of PDT, and the application of classic PS in CRC. The action process and damage mechanism of photothermal therapy (PTT) and the types of ablation agents. In addition, we present the imaging examination and the application of PDT / PTT in tumor, including (fluorescence imaging, photoacoustic imaging, nuclear magnetic resonance imaging, nuclear imaging) to provide the basis for the early diagnosis of CRC. Notably, single phototherapy has several limitations in vivo, especially for deep tumors. Here, we discuss the advantages of the combination therapy of PDT and PTT compared with the single therapy. At the same time, this review summarizes the clinical application of PS in CRC. Although a variety of nanomaterials are in the research and development stage, few of them are actually on the market, they will show great advantages in the treatment of CRC in the near future. © The author(s).Entities:
Keywords: colorectal cancer; nanoparticle.; photodynamic therapy; photosensitizer; photothermal therapy
Mesh:
Substances:
Year: 2021 PMID: 33867852 PMCID: PMC8040477 DOI: 10.7150/ijbs.58773
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 5Mechanism of photodynamic reaction and targets of ROS singlet ground state. The Ps transits from singlet ground state to triplet ground state and produces ROS through type I reaction, and ROS can mediate tumor cell death by acting on various organelles and tumor microvessels.
Figure 7Molecular structure formula of some PSs.
Figure 8Schematic diagram of multimodal targeted PTT nanomedicine.
Comparison of phototherapy and other cancer treatments.
| Tumor treatment | Cytotoxicity | Drug metabolic rate | Selectivity | Security | Traumatic | Synergy | Risk |
|---|---|---|---|---|---|---|---|
| Photodynamic therapy | Low | High | High | High | Low | High | Low |
| Surgical treatment | Secondary | Secondary | Secondary | Low | High | Secondary | High |
| Chemoradiotherapy | High | Low | Low | Low | High | Secondary | High |
Application of PS in PTT / PDT.
| Number | PS | Product Category | Highest Phase |
|---|---|---|---|
| 1 | Padeliporfin potassium | PDT | Launched-2018 |
| 2 | Aminolevulinic acid hexyl ester | PDT | Launched-2005 |
| 3 | Mono-L-aspartyl chlorin e6 | PDT | Launched-2004 |
| 4 | Temoporfin | PDT | Launched-2002 |
| 5 | Methyl aminolevulinate | PDT | Launched-2001 |
| 6 | 5-Aminolevulinic acid hydrochloride | PDT | Launched-2000 |
| 7 | Cetuximab-IRDye-700DX | PDT | Pre-Registered |
| 8 | Tin-mesoporphyrin | PDT | Pre-Registered |
| 9 | SNA-001 (Code came) | PTT | Phase III |
| 10 | ACP-SL017 (Code came) | PDT | Phase III |
| 11 | Rose Bengal disodium | PDT | Phase III |
| 12 | Hypericin | PDT | Phase III |
| 13 | inCVAX | PTT | Phase II/III |
| 14 | Tin ethyl etiopurpurin dichloride | PDT | Phase II/III |
| 15 | Deuteporfin | PDT | Phase II |
| 16 | TLD-1433 (Code came) | PDT | Phase II |
| 17 | Fimaporfin/gemcitabine | PDT | Phase II |
| 18 | Exeporfinium chloride | PDT | Phase II |
| 19 | Photochlor | PDT | Phase II |
| 20 | Tin (IV) protoporphyrin IX dichloride | PDT | Phase II |
| 21 | Lemuteporphin | PDT | Phase II |
| 22 | Lutetium texaphyrin | PDT | Phase II |
| 23 | Redaporfin | PDT | Phase I/II |
| 24 | Fimaporfin/bleomycin | PDT | Phase I/II |
| 25 | Photocyanine | PDT | Phase I |
| 26 | Silicon phthalocyanine 4 | PDT | Phase I |
| 27 | Aminolevulinic acid benzyl ester | PDT | Phase I |
| 28 | Rhodamine 123 | PDT | Phase I |
| 29 | Fimaporfin | PDT | Clinical |
| 30 | Nanoshells | PTT | Clinical |
| 31 | Sinoporphyrin sodium | PDT | Preclinical |
| 32 | XF-70 (Code came) | PDT | Preclinical |